Merck is a healthcare manufacturer and distributor of pharmaceuticals. The Company operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Employee Rating

3.7More
TypePublic
HQKenilworth, US
Founded1891
Size (employees)69,000 (est)
Websitemerck.com
Merck was founded in 1891 and is headquartered in Kenilworth, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Merck

Kenneth Frazier

Kenneth Frazier

Chairman of the Board, CEO
Jim Scholefield

Jim Scholefield

Chief Information and Digital Officer
Robert Davis

Robert Davis

EVP, CFO
Mirian Graddick-Weir

Mirian Graddick-Weir

EVP
Julie Gerberding

Julie Gerberding

EVP
Sanat Chattopadhyay

Sanat Chattopadhyay

President, EVP
Show more

Merck Office Locations

Merck has offices in Pensacola, Bridgeport, Toms River, Suffolk and in 273 other locations
Kenilworth, US (HQ)
2000 Galloping Hill Road
Boston, US
33 Avenue Louis Pasteur
Lansdale, US
770 Sumneytown Pike
North Wales, US
351 N Sumneytown Pike
Rahway, US
126 E Lincoln Ave
Sydney, AU
54-68 Ferndell Street, South Granville
Show all (278)
Report incorrect company information

Merck Financials and Metrics

Merck Revenue

Merck's revenue was reported to be $40.12 b in FY, 2017
USD

Revenue (Q3, 2018)

10.8b

Net income (Q3, 2018)

2.0b

Market capitalization (9-Nov-2018)

194.7b

Closing stock price (9-Nov-2018)

74.9

Cash (30-Sep-2018)

7.8b

EV

206.8b
Merck's current market capitalization is $194.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

44.0b42.2b39.5b39.8b40.1b

Revenue growth, %

(4%)(6%)1%

Cost of goods sold

16.0b15.2b14.4b

Gross profit

28.1b27.1b25.1b
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

9.8b10.1b9.3b9.8b10.5b9.4b9.9b10.3b10.0b10.5b10.8b

R&D expense

1.7b1.5b1.7b2.2b1.7b1.8b1.7b4.4b3.2b2.3b2.1b

Operating expense total

1.7b1.5b1.7b2.2b1.7b1.8b1.7b4.4b3.2b5.5b2.1b

Depreciation and amortization

(1.6b)
Annual
usdY, 2009Y, 2010Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.3b10.9b13.5b13.5b15.6b7.4b8.5b6.5b6.1b

Accounts Receivable

7.2b6.6b6.5b7.0b6.9b

Inventories

6.2b5.6b4.7b4.9b5.1b

Current Assets

35.7b33.2b29.8b30.6b24.8b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

14.1b15.8b9.7b11.4b8.0b6.9b7.5b9.7b6.6b7.9b11.7b7.8b7.9b4.5b5.3b7.8b

Accounts Receivable

7.6b7.2b7.0b6.5b6.7b6.5b6.4b6.9b6.9b7.4b7.1b7.4b7.7b7.2b7.3b7.4b

Inventories

6.7b6.4b6.1b5.8b5.5b5.3b5.1b5.1b5.2b5.2b5.1b5.4b5.3b5.4b5.2b5.4b

Current Assets

37.8b41.2b33.6b34.7b32.9b28.3b28.6b28.8b27.9b29.4b31.5b28.2b27.9b24.1b24.1b26.8b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.5b11.9b4.5b3.9b2.4b

Depreciation and Amortization

4.6b

Inventories

(365.0m)79.0m805.0m206.0m(145.0m)

Accounts Payable

522.0m593.0m(37.0m)278.0m254.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

3.7b1.7b3.8b4.6b1.6b3.5b1.1b2.3b4.5b1.6b3.5b3.5b741.0m2.5b4.4b

Depreciation and Amortization

5.0b1.8b3.5b5.1b3.2b4.8b1.6b3.1b4.3b1.2b2.4b3.5b1.1b2.4b3.4b

Cash From Operating Activities

8.6b2.4b4.7b9.0b4.9b8.2b2.2b3.8b6.7b286.0m3.6b2.4b1.2b4.5b7.3b

Cash From Investing Activities

(4.3b)(3.8b)(3.9b)(7.6b)(4.1b)(4.1b)1.7b243.0m(647.0m)3.2b2.1b2.7b(197.0m)476.0m2.1b
USDY, 2018

EV/CFO

28.2 x

EV/FCF

36.6 x

Revenue/Employee

156.4k

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.6 x
Show all financial metrics

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018

Drugs Approved by FDA

1

Phase III Trials Products

24 20

Products

30

Projects in R&D Pipeline

41 10
Show all operating metrics

Merck Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
ViralyticsFebruary 21, 2018$502 m
StayWellJuly 11, 2016
Afferent PharmaceuticalsJune 09, 2016$1.25 b
IOmet PharmaJanuary 13, 2016
cCAM BiotherapeuticsJuly 28, 2015$95 m
OncoEthixDecember 18, 2014$375 m
Cubist Pharmaceuticals, Inc.December 08, 2014$8.40 b
PreventiceSeptember 11, 2014
Peer+June 30, 2014
Idenix PharmaceuticalsJune 09, 2014$3.85 b
Show more

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 88.3% from Pharmaceutical, 8.7% from Animal Health and 3.0% from Other

Report incorrect company information

Merck Online and Social Media Presence

Embed Graph
Report incorrect company information

Merck News and Updates

Genitourinary Drugs Market Analysis 2018: Astellas, Pfizer, Eli Lilly, Bayer AG, Merck, Abbott Laboratories, Bristol-Myers Squibb, Genentech, Roche, GlaxoSmithKline

"Genitourinary Drugs Market", published by Qurate Research, provides extensive insight and analysis of the Genitourinary Drugs Market over the next eight years (2018-2023) and acts as a vital point of reference for operators or suppliers. Posted via Industry Today. Follow us on Twitter @IndustryToda…

Laboratory Water Purifier Market by Leading Competitors Thermo Fisher Scientific Inc., Sartorius, Pall Corporation, Biobase, TECNO-GAZ, SUEZ (Purite Ltd), Labconco, Aurora Instruments, Biosan, Merck Millipore, Heal Force, ELGA LabWater, ResinTech

"Laboratory Water Purifier Market", published by Qurate Research, provides extensive insight and analysis of the Laboratory Water Purifier Market over the next eight years (2018-2023) and acts as a vital point of reference for operators or suppliers. Posted via Industry Today. Follow us on Twitter @…

COPD Drugs Global Market 2018 Top Key Players – Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca and Forecast to 2025

Wiseguyreports.Com Added New Market Research Report On -“Global COPD Drugs Market 2018 Top Key Players, Production , Growth and Future Demand Forecast to 2025 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Cell Culture Products Global Market 2018 Top Key Players – Life Technologies , Corning (Cellgro) , Sigma-Aldrich , Thermo Fisher , Merck Millipore and Forecast to 2025

Wiseguyreports.Com Added New Market Research Report On -“Global Cell Culture Products Market 2018 Top Key Players, Production , Growth and Future Demand Forecast to 2025 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Fetal Bovine Serum 2018 Global Market Key Players – Life Technologies, Thermo Fisher, GE Healthcare, Sigma-Aldrichm, Merck, Moregate BioTech – Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Fetal Bovine Serum Market Insights, Forecast to 2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information

Merck Blogs

Merck Reaffirms Commitment to Increase Vaccine Production and Clarifies Rotavirus Vaccine Transition Plan with Gavi Countries

Vaccines are one of the greatest public health success stories in history. Merck has played an important part in that story, and our commitment to help prevent diseases continues. Language: English read more

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Dateline City: KENILWORTH, N.J. Approval Based on Results of Phase 3 KEYNOTE-407 Trial, Which Demonstrated Superior Overall Survival with KEYTRUDA in Combination with Chemother…

Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization

Dateline City: KENILWORTH, N.J. Increases Quarterly Dividend 15% to $0.55 per Outstanding Share Enters Into a $5 Billion Accelerated Share Repurchase Program Under Expande…

Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

Dateline City: KENILWORTH, N.J. Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS≥20 and CPS≥1 and in Total Patient Populati…

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma

Dateline City: KENILWORTH, N.J. Opinion Granted Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Pivotal Phase 3 EORTC1325/KEYNOTE-054 Trial …

SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer

Dateline City: KENILWORTH, N.J. 60 Percent of Patients Receiving LYNPARZA Remained Progression-Free at Three Years Compared to 27 Percent on Placebo Following Platinum-Based Ch…
Show more

Merck Company Life and Culture

Report incorrect company information

Merck Frequently Asked Questions

  • When was Merck founded?

    Merck was founded in 1891.

  • Who are Merck key executives?

    Merck's key executives are Kenneth Frazier, Jim Scholefield and Robert Davis.

  • How many employees does Merck have?

    Merck has 69,000 employees.

  • What is Merck revenue?

    Latest Merck annual revenue is $40.1 b.

  • What is Merck revenue per employee?

    Latest Merck revenue per employee is $581.5 k.

  • Who are Merck competitors?

    Competitors of Merck include Merck, CVS and Pfizer.

  • Where is Merck headquarters?

    Merck headquarters is located at 2000 Galloping Hill Road, Kenilworth.

  • Where are Merck offices?

    Merck has offices in Pensacola, Bridgeport, Toms River, Suffolk and in 273 other locations.

  • How many offices does Merck have?

    Merck has 278 offices.